Pharmalucence Builds New Drug Production Facility in Massachusetts
06/04/2010
"Pharmalucence has long maintained a strong radiopharmaceutical business in Massachusetts," said Glenn Alto, president and CEO of Pharmalucence. "We are investing to fully replace and modernize our infrastructure to ensure we maintain our local presence going forward."
The investment was aided by a $20 million bond issued by MassDevelopment, the first use of the Recovery Zone Facility Bond program in the state. The bond is one component of the American Recovery and Reinvestment Act to stimulate the economy with low-cost financing.
Pharmalucence produces eight drugs to treat cancers and heart disease. Construction on the new facility will begin this summer, and the plant is expected to be operational by the end of 2012.
Project Announcements
Tate Plans Glasgow, Kentucky, Manufacturing Operations
10/28/2025
Electrolux Consumer Products Expands Kinston, North Carolina, Manufacturing Operations
10/28/2025
Canada-Based MST Rebar Plans Bladenboro, North Carolina, Manufacturing Operations
10/28/2025
Cardinal Biologicals Expands Cape Girardeau, Missouri, Operations
10/27/2025
Whirlpool Expands Clyde-Marion, Ohio, Production Operations
10/27/2025
Imperial Systems Plans Pennsylvania, Manufacturing Operations
10/27/2025
Most Read
-
2025’s Top States for Business: How the Winners Are Outpacing the Rest
Q3 2025
-
The Compliance Reckoning Is Here
Q3 2025
-
Around the Horn: Data Center Supply Chains — What's Next?
Q3 2025
-
How Consumer Trends Are Reshaping Food Facilities
Q3 2025
-
Powering the Next Generation of Projects
Q3 2025
-
First Person: Filter King’s Expansion Playbook
Q3 2025
-
Rethinking Auto Site Strategy in the Age of Tariffs and Powertrain Shifts
Q3 2025